

Scientific Motivation

Breakthroughs in cancer research within the last decade have revolutionised our understanding of the molecular pathology of cancer. Nevertheless, the success of most of the currently available targeted cancer therapies is limited and the development of novel treatment options is slow. To accelerate the translation of research findings to novel therapeutics, the German Cancer Research Center and Bayer HealthCare have joined forces and set up a strategic alliance in 2008.

The Symposium is held within the framework of this partnership and is the second of its kind. It will bring together preclinical and clinical scientists as well as pharma researchers to present their recent findings relevant to the identification of novel targets or the development of novel therapeutic strategies.

The goal is to discuss established and emerging targeted cancer therapies. Scientific and clinical aspects will be reviewed in the context of oncogenomics, cancer stem cells, and immunotherapy. We cordially invite you to the stimulating environment and "scientific hot spot" of Heidelberg to discuss with us options to translate scientific ideas to novel treatment options.

Scientific Organizing Committee

Philipp Beckhove, DKFZ . Volker Gekeler, BHC .
Christof von Kalle, DKFZ, NCT . Bertolt Kreft, BHC .
Peter Lichter, DKFZ . Dominik Mumberg, BHC .
Andreas Trumpp, DKFZ . Otmar D. Wiestler, DKFZ .
Karl Ziegelbauer, BHC .

General Information

Venue

German Cancer Research Center (DKFZ)
Communication Center
Im Neuenheimer Feld 280
69120 Heidelberg, Germany
<http://www.dkfz.de>

Registration

www.dkfz.de/en/symposiumTCT/

Scientific Coordination and Local Organisation

Ruth Wellenreuther
German Cancer Research Center (DKFZ)
Heidelberg
Phone +49. 6221. 42 21 69
Mobile +49. 173. 904 86 14
e-mail r.wellenreuther@dkfz-heidelberg.de

Ingrid Fryson
German Cancer Research Center (DKFZ)
Heidelberg
Phone +49. 6221. 42 37 16
e-mail i.fryson@dkfz-heidelberg.de

dkfz.

GERMAN
CANCER RESEARCH CENTER
IN THE HELMHOLTZ ASSOCIATION



Bayer HealthCare

dkfz.

GERMAN
CANCER RESEARCH CENTER
IN THE HELMHOLTZ ASSOCIATION

2nd Symposium :Targeted Cancer Therapy.



November 19 – 20, 2012

German Cancer Research Center (DKFZ)
Heidelberg

Programme

Monday, November 19, 2012

Opening

- 14:00 OTMAR WIESTLER
Chairman and Scientific Director
German Cancer Research Center (DKFZ), Heidelberg
Welcome address
- 14:15 ANDREAS BUSCH
Head of Global Drug Discovery
Bayer HealthCare
Welcome address
- 14:30 **Keynote lecture I**
DOUGLAS HANAHAN
Swiss Institute for Experimental Cancer Research (ISREC),
EPFL, Lausanne, Switzerland
:Lessons in translational oncology from mouse models
of cancer.
- 15:30 Coffee break
- Session I :Oncogenomics.**
Chairs: PETER LICHTER . VOLKER GEKELER
- 16:00 EWAN BIRNEY
European Bioinformatics Institute (EBI), Hinxton, UK
:ENCODE: an initial systematic analysis of non-coding
DNA.
- 16:30 MARK A. RUBIN
Weill Cornell Medical College, New York, USA
:First steps in precision medicine for prostate cancer:
defining molecular subclasses.

Monday, November 19, 2012

- 17:00 STEFAN M. PFISTER
German Cancer Research Center (DKFZ), Heidelberg,
Germany
:Childhood brain tumors – new paradigms for treat-
ment decisions based on tumor biology.
- 17:30 MANEL ESTELLER
Bellvitge Biomedical Research Institute (IDIBELL),
Barcelona, Spain
:Pharmacogenetics and epigenetic drugs.
- 18:00 Reception

Tuesday, November 20, 2012

- Session II :Cancer Stem Cells.**
Chairs: ANDREAS TRUMPP . DOMINIK MUMBERG
- 9:00 EDUARD BATLLE
Institute for Research in Biomedicine (IRB), Barcelona,
Spain
:From colon stem cells to colorectal cancer.
- 9:30 RAVI MAJETI
Stanford University Cancer Center, California, USA
:Targeting CD47 with blocking monoclonal antibodies
in human hematologic malignancies.
- 10:00 JÖRG HÜLSKEN
Swiss Institute for Experimental Cancer Research (ISREC),
EPFL, Lausanne, Switzerland
:Metastatic colonization: new opportunities for thera-
peutic intervention.
- 10:30 TIM HOEY
OncoMed Pharmaceuticals, Redwood City, California,
USA
:Development of OMP-18R5, a novel Wnt signaling
antagonist that reduces cancer stem cell frequency.
- 11:00 Coffee break

Tuesday, November 20, 2012

- 11:30 **Keynote lecture II**
THOMAS F. GAJEWSKI
University of Chicago, USA
:Immunotherapeutic targets for melanoma
identified through interrogation of the tumor
microenvironment.
- 12:30 Lunch reception
- Session III :Immunotherapy.**
Chairs: PHILIPP BECKHOVE . BERTOLT KREFT
- 14:00 HANSJÖRG SCHILD
Institute for Immunology, University Medical Center
Mainz, Germany
:Mechanisms controlling the stimulatory capacity
of dendritic cells.
- 14:30 LAURENCE ZITVOGEL
Institut Gustave Roussy, Villejuif, France
:Immune-off target effects of anticancer therapies.
- 15:00 BENNO RATTEL
Amgen Research, Munich, Germany
:Immunotherapy with BiTE antibodies: lessons
learned from blinatumomab.
- 15:30 ALEXANDER LESOKHIN
Memorial Sloan-Kettering Cancer Center, New York,
USA
:Biomarkers of response to ipilimumab.
- 16:00 End of symposium